---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-134758"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:42:20.513369+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma Q1 Royalty Receipts +14% to $705M; FY2024 guidance reaffirmed

## Summary
- Portfolio Receipts of $717M, down 37% from $1,131M YoY due to $475M Biohaven milestone in Q1 2023.
- Royalty Receipts grew 14% to $705M, led by Evrysdi, Trelegy, and the cystic fibrosis franchise.
- Full-year 2024 Portfolio Receipts guidance reaffirmed at $2.6B–$2.7B, with Royalty Receipts growth of 5%–9%.
- Announced ~$525M acquisition of royalties on Sanofi’s frexalimab (Phase 3 multiple sclerosis); $5.9B total liquidity.

## SEC filing metadata
- accession: 0001193125-24-134758
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312524134758/0001193125-24-134758-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312524134758/d834416d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-134758
- JSON: https://secwatch.observer/filing/0001193125-24-134758.json
- Plain text: https://secwatch.observer/filing/0001193125-24-134758.txt

## Key facts
- Earnings Releases
  Royalty Pharma plc updated its first quarter of 2024 guidance (reaffirmed).
  - Period: first quarter of 2024
  - Guidance: reaffirmed
  - Result: reported results
  source text: On May 9, 2024, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000119312524134758/0001193125-24-134758-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.